Developer docs
API playgroundTry for free, no card

Search company profiles

Complement Therapeutics

Full company profile

uuid0000l56

Namestring
Complement Therapeutics
Legal namestring
Complement Therapeutics Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Complement Therapeutics is a clinical-stage biotechnology company developing therapeutics for complement-mediated diseases, with its primary focus on geographic atrophy (GA) secondary to age-related macular degeneration (AMD) — a condition affecting over 5 million people globally that currently has no approved treatment. The company was spun out of the University of Manchester in 2021, founded on pioneering research by Prof Simon Clark, Prof Paul Bishop, and Dr Richard Unwin into the role of Factor H-Related (FHR) proteins in AMD pathogenesis, published in Nature Communications (2020) and the American Journal of Human Genetics (2021). Its lead asset CTx001 is an AAV2-based gene therapy that delivers mini-CR1 (a truncated, secreted form of Complement Receptor 1) via subretinal injection, enabling sustained modulation of both the classical and alternative complement pathways from a single administration with broad ocular biodistribution including the choriocapillaris. The company also operates the Complement Precision Medicine (CPM) platform, a proprietary mass spectrometry system for simultaneous quantification of complement proteins from blood samples to support patient stratification and disease monitoring.

The company operates a pre-revenue clinical-stage business model in which future revenue is contingent on commercialization of CTx001 either independently or through partnership or acquisition by a larger pharmaceutical company following clinical validation. Current operations span three jurisdictions: Complement Therapeutics GmbH in Munich (German headquarters), Complement Therapeutics Ltd in London and Stevenage (UK subsidiary with research laboratories at Stevenage Bioscience Catalyst), and Complement Therapeutics Inc in the United States (supporting US clinical operations). Manufacturing of CTx001 clinical supply is conducted through a strategic partnership with Pharmaron at GMP facilities in Liverpool, UK. Clinical trials are conducted at leading retinal centers, with the i-GAIN natural history study enrolling over 230 participants across 12 UK sites and 10 US centers, and the Opti-GAIN Phase I/II trial designed for 75 participants with GA secondary to AMD.

The company has raised approximately €77 million in disclosed venture funding (€5M seed in February 2022 from BioGeneration Ventures and Forbion; €72M Series A in April 2023 led by Gimv and Forbion with participation from BGV, Panakès Partners, Cambridge Innovation Capital, Hadean Ventures, and Seroba Life Sciences). Complement Therapeutics has assembled a leadership team with deep ophthalmology and gene therapy experience drawn from Bayer, Novartis, Alexion, Genzyme, Autolus, and Prothelia. The company has secured multiple regulatory designations — MHRA Innovation Passport (November 2022), FDA IND clearance (October 2025), FDA Fast Track Designation (January 2026), and UK CTA approval (January 2026) — and dosed its first patient in the Opti-GAIN Phase I/II trial in March 2026, completing Cohort 1 dosing with favorable IDMC recommendation to proceed with dose escalation in May 2026.

Short descriptiontext

Complement Therapeutics is a clinical-stage biotechnology company developing AAV2-based gene therapies for complement-mediated diseases, with lead asset CTx001 in Phase I/II trials for geographic atrophy secondary to AMD. Founded 2021, spun out of the University of Manchester.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, complement system therapeutics, biopharmaceutical research, ocular disease treatments, precision medicine diagnostics
Industry4 codes
PRIMARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Gene Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotech. Revenue expected from commercialization of CTx001 upon regulatory approval. Business model based on developing novel therapeutics through clinical trials and either commercializing directly or through partnership/acquisition by larger pharmaceutical company.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Complement Therapeutics is a clinical-stage biotechnology company developing an investigational AAV2-based gene therapy (CTx001) that delivers mini-CR1 to provide sustained modulation of complement pathways for the treatment of Geographic Atrophy secondary to age-related macular degeneration. The company also operates a proprietary Complement Precision Medicine (CPM) mass spectrometry platform that simultaneously quantifies multiple complement proteins from a single blood sample to support patient stratification and disease monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I/II Opti-GAIN trial enrolling 75 participants with 2-year safety/efficacy assessment plus 5-year follow-up
+2 more records
Product overview1 text field

Complement Therapeutics is developing a portfolio of treatments for complement-mediated diseases, with two primary offerings: CTx001 as the lead AAV2-based gene therapy product for Geographic Atrophy secondary to AMD, and the Complement Precision Medicine (CPM) Platform as a diagnostic companion tool for patient stratification and disease monitoring. The company is also developing additional therapeutic candidates aimed at systemic modulation of the complement system for non-ocular indications.

Product and service2 records
1CTx001
CategoryGene Therapy / Lead Therapeutic Asset
Description

An investigational AAV2-based gene therapy candidate designed to deliver mini-CR1 (a truncated and secreted form of Complement Receptor 1) for the treatment of Geographic Atrophy secondary to Age-related Macular Degeneration. CTx001 enables sustained local modulation of multiple complement pathways following a single subretinal injection, with the potential to provide durable, one-time treatment benefits. Currently in Phase I/II Opti-GAIN clinical trial with 75 participants planned.

2Complement Precision Medicine (CPM) Platform
CategoryDiagnostic / Precision Medicine Platform
Description

A proprietary mass spectrometry-based platform that enables the simultaneous measurement of an array of complement proteins from a single systemically drawn blood sample, including C3 and its breakdown products, Factor I, Factor H, FHL-1, and the FHR family of proteins. The platform facilitates patient stratification and disease monitoring for clinical trials and supports the subsequent commercialization of therapeutic assets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

Two-year collaborative project to intensify perfusion processes and standardize AAV manufacturing for systemic diseases. Awarded over £1 million Innovate UK grant. Partnership involves Touchlight and Pharmaron Biologics.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

Collaboration on innovative rAAV production using Touchlight's enzyme-based doggybone DNA (dbDNA) manufacturing platform. Project aims to improve AAV yield and lower manufacturing costs compared to traditional plasmid DNA production.

Strategic tierMajorTypeOthersAnnounced on2023-06-13
Description

World-leading biotech cluster housing state-of-the-art laboratory facilities. Complement Therapeutics opened research labs at SBC campus in Stevenage, UK for advancing pipeline asset development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-29
Description

Strategic partnership for development and clinical manufacture of CTx001 gene therapy. Project commenced December 2022 at Pharmaron's GMP facilities in Liverpool, UK. CMC team provides technical expertise in ocular gene therapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-23
Description

Company spun out from University of Manchester based on pioneering research by founders Prof Simon Clark, Prof Paul Bishop, and Dr Richard Unwin into FHR proteins and complement cascade.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biotech whose lead product Syfovre (pegcetacoplan) is an approved C3 inhibitor for geographic atrophy secondary to AMD. Most direct commercial competitor to CTx001 in the same indication, with established physician relationships and reimbursement infrastructure.

TypeDirect peer
Description

Acquired Iveric Bio in 2023 to gain Izervay (avacincaptad pegol), a C5 inhibitor approved for geographic atrophy. Direct complement-pathway competitor in the same indication, with global commercial reach that CTx001 would ultimately need to compete against or partner with.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD. Comparable as an AAV gene therapy developer in ophthalmology with similar modality, regulatory pathway, and manufacturing challenges.

TypeDirect peer
Description

Gene therapy company with an AAV platform and clinical programs in retinal diseases (ABBV-RGX-314 for wet AMD via subretinal/suprachoroidal delivery). Closely comparable modality (AAV ocular gene therapy), delivery route overlap, and development-stage proximity.

TypeDirect peer
Description

Acquired by Novartis in 2021 for ~$800M; developed GT005, an AAV-based gene therapy targeting complement factor I for geographic atrophy. Highly comparable therapeutic mechanism (complement modulation via AAV gene therapy in GA) and indication overlap.

TypeBroad incumbent
Description

Established rare-disease biotech with multiple approved AAV-based gene therapies (e.g., Roctavian for hemophilia A). Relevant as a gene therapy commercialization benchmark and potential strategic acquirer of platform AAV/complement assets.

TypeBroad incumbent
Description

Roche-owned gene therapy subsidiary (Luxturna) with AAV ocular and other gene therapy capabilities. Comparable as a commercial-stage AAV gene therapy player; relevant strategic acquirer for ophthalmology-focused gene therapy platforms.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies with programs in CNS and other indications. Comparable as an AAV gene therapy developer facing similar manufacturing, regulatory, and clinical-stage challenges.

TypeBroad incumbent
Description

Develops Eylea (aflibercept), the standard-of-care anti-VEGF for wet AMD with multi-billion-dollar franchise, and has early-stage pipeline interest in dry AMD/GA. Strategic acquirer profile and relevant comparator for ophthalmology commercial dynamics.

TypeDirect peer
Description

Clinical-stage complement-focused biotech developing classical-pathway inhibitors (C1q antagonists) for geographic atrophy and other complement-mediated diseases. Closely comparable as a complement-pathway therapeutic competitor targeting similar indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Complement Therapeutics

Gene Therapycomplementtx.com

Complement Therapeutics is a clinical-stage biotechnology company developing AAV2-based gene therapies for complement-mediated diseases, with lead asset CTx001 in Phase I/II trials for geographic atrophy secondary to AMD. Founded 2021, spun out of the University of Manchester.

What Complement Therapeutics does

Complement Therapeutics is a clinical-stage biotechnology company developing therapeutics for complement-mediated diseases, with its primary focus on geographic atrophy (GA) secondary to age-related macular degeneration (AMD) — a condition affecting over 5 million people globally that currently has no approved treatment. The company was spun out of the University of Manchester in 2021, founded on pioneering research by Prof Simon Clark, Prof Paul Bishop, and Dr Richard Unwin into the role of Factor H-Related (FHR) proteins in AMD pathogenesis, published in Nature Communications (2020) and the American Journal of Human Genetics (2021). Its lead asset CTx001 is an AAV2-based gene therapy that delivers mini-CR1 (a truncated, secreted form of Complement Receptor 1) via subretinal injection, enabling sustained modulation of both the classical and alternative complement pathways from a single administration with broad ocular biodistribution including the choriocapillaris. The company also operates the Complement Precision Medicine (CPM) platform, a proprietary mass spectrometry system for simultaneous quantification of complement proteins from blood samples to support patient stratification and disease monitoring.

The company operates a pre-revenue clinical-stage business model in which future revenue is contingent on commercialization of CTx001 either independently or through partnership or acquisition by a larger pharmaceutical company following clinical validation. Current operations span three jurisdictions: Complement Therapeutics GmbH in Munich (German headquarters), Complement Therapeutics Ltd in London and Stevenage (UK subsidiary with research laboratories at Stevenage Bioscience Catalyst), and Complement Therapeutics Inc in the United States (supporting US clinical operations). Manufacturing of CTx001 clinical supply is conducted through a strategic partnership with Pharmaron at GMP facilities in Liverpool, UK. Clinical trials are conducted at leading retinal centers, with the i-GAIN natural history study enrolling over 230 participants across 12 UK sites and 10 US centers, and the Opti-GAIN Phase I/II trial designed for 75 participants with GA secondary to AMD.

The company has raised approximately €77 million in disclosed venture funding (€5M seed in February 2022 from BioGeneration Ventures and Forbion; €72M Series A in April 2023 led by Gimv and Forbion with participation from BGV, Panakès Partners, Cambridge Innovation Capital, Hadean Ventures, and Seroba Life Sciences). Complement Therapeutics has assembled a leadership team with deep ophthalmology and gene therapy experience drawn from Bayer, Novartis, Alexion, Genzyme, Autolus, and Prothelia. The company has secured multiple regulatory designations — MHRA Innovation Passport (November 2022), FDA IND clearance (October 2025), FDA Fast Track Designation (January 2026), and UK CTA approval (January 2026) — and dosed its first patient in the Opti-GAIN Phase I/II trial in March 2026, completing Cohort 1 dosing with favorable IDMC recommendation to proceed with dose escalation in May 2026.

Complement Therapeutics firmographics

Firmographics
Name
Complement Therapeutics
Legal name
Complement Therapeutics Limited
Website
https://complementtx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Complement Therapeutics is a clinical-stage biotechnology company developing AAV2-based gene therapies for complement-mediated diseases, with lead asset CTx001 in Phase I/II trials for geographic atrophy secondary to AMD. Founded 2021, spun out of the University of Manchester.
Ownership category
akta.pro rank

Complement Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Gene therapy development
  • Complement system therapeutics
  • Biopharmaceutical research
  • Ocular disease treatments
  • Precision medicine diagnostics

Where Complement Therapeutics is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

Complement Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Development and Commercialization: Pre-revenue clinical stage biotech. Revenue expected from commercialization of CTx001 upon regulatory approval. Business model based on developing novel therapeutics through clinical trials and either commercializing directly or through partnership/acquisition by larger pharmaceutical company.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Complement Therapeutics product offering

Product offering

Core offering

Complement Therapeutics is a clinical-stage biotechnology company developing an investigational AAV2-based gene therapy (CTx001) that delivers mini-CR1 to provide sustained modulation of complement pathways for the treatment of Geographic Atrophy secondary to age-related macular degeneration. The company also operates a proprietary Complement Precision Medicine (CPM) mass spectrometry platform that simultaneously quantifies multiple complement proteins from a single blood sample to support patient stratification and disease monitoring.

Product overview

Complement Therapeutics is developing a portfolio of treatments for complement-mediated diseases, with two primary offerings: CTx001 as the lead AAV2-based gene therapy product for Geographic Atrophy secondary to AMD, and the Complement Precision Medicine (CPM) Platform as a diagnostic companion tool for patient stratification and disease monitoring. The company is also developing additional therapeutic candidates aimed at systemic modulation of the complement system for non-ocular indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • CTx001 An investigational AAV2-based gene therapy candidate designed to deliver mini-CR1 (a truncated and secreted form of Complement Receptor 1) for the treatment of Geographic Atrophy secondary to Age-related Macular Degeneration. CTx001 enables sustained local modulation of multiple complement pathways following a single subretinal injection, with the potential to provide durable, one-time treatment benefits. Currently in Phase I/II Opti-GAIN clinical trial with 75 participants planned.
  • Complement Precision Medicine (CPM) Platform A proprietary mass spectrometry-based platform that enables the simultaneous measurement of an array of complement proteins from a single systemically drawn blood sample, including C3 and its breakdown products, Factor I, Factor H, FHL-1, and the FHR family of proteins. The platform facilitates patient stratification and disease monitoring for clinical trials and supports the subsequent commercialization of therapeutic assets.

Quantifiable outcome

  • Phase I/II Opti-GAIN trial enrolling 75 participants with 2-year safety/efficacy assessment plus 5-year follow-up
  • +2 more outcomes

Companies that use Complement Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Complement Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Complement Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • Cell and Gene Therapy Catapult (CGT Catapult)coreStrategic or Co-development Partner · 9 May 2024Two-year collaborative project to intensify perfusion processes and standardize AAV manufacturing for systemic diseases. Awarded over £1 million Innovate UK grant. Partnership involves Touchlight and Pharmaron Biologics.
  • TouchlightmajorStrategic or Co-development Partner · 9 May 2024Collaboration on innovative rAAV production using Touchlight's enzyme-based doggybone DNA (dbDNA) manufacturing platform. Project aims to improve AAV yield and lower manufacturing costs compared to traditional plasmid DNA production.
  • Stevenage Bioscience CatalystmajorOthers · 13 June 2023World-leading biotech cluster housing state-of-the-art laboratory facilities. Complement Therapeutics opened research labs at SBC campus in Stevenage, UK for advancing pipeline asset development.
  • PharmaroncoreStrategic or Co-development Partner · 29 March 2023Strategic partnership for development and clinical manufacture of CTx001 gene therapy. Project commenced December 2022 at Pharmaron's GMP facilities in Liverpool, UK. CMC team provides technical expertise in ocular gene therapy development.
  • University of ManchestercoreStrategic or Co-development Partner · 23 February 2022Company spun out from University of Manchester based on pioneering research by founders Prof Simon Clark, Prof Paul Bishop, and Dr Richard Unwin into FHR proteins and complement cascade.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Complement Therapeutics competitors and assessment

Company assessment

Direct peers

  • Apellis Pharmaceuticals: Commercial-stage biotech whose lead product Syfovre (pegcetacoplan) is an approved C3 inhibitor for geographic atrophy secondary to AMD. Most direct commercial competitor to CTx001 in the same indication, with established physician relationships and reimbursement infrastructure.
  • Astellas Pharma (Iveric Bio): Acquired Iveric Bio in 2023 to gain Izervay (avacincaptad pegol), a C5 inhibitor approved for geographic atrophy. Direct complement-pathway competitor in the same indication, with global commercial reach that CTx001 would ultimately need to compete against or partner with.
  • REGENXBIO: Gene therapy company with an AAV platform and clinical programs in retinal diseases (ABBV-RGX-314 for wet AMD via subretinal/suprachoroidal delivery). Closely comparable modality (AAV ocular gene therapy), delivery route overlap, and development-stage proximity.
  • Gyroscope Therapeutics (Novartis): Acquired by Novartis in 2021 for ~$800M; developed GT005, an AAV-based gene therapy targeting complement factor I for geographic atrophy. Highly comparable therapeutic mechanism (complement modulation via AAV gene therapy in GA) and indication overlap.
  • uniQure: Clinical-stage gene therapy company developing AAV-based therapies with programs in CNS and other indications. Comparable as an AAV gene therapy developer facing similar manufacturing, regulatory, and clinical-stage challenges.
  • Annexon Biosciences: Clinical-stage complement-focused biotech developing classical-pathway inhibitors (C1q antagonists) for geographic atrophy and other complement-mediated diseases. Closely comparable as a complement-pathway therapeutic competitor targeting similar indications.

Emerging players

  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD. Comparable as an AAV gene therapy developer in ophthalmology with similar modality, regulatory pathway, and manufacturing challenges.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease biotech with multiple approved AAV-based gene therapies (e.g., Roctavian for hemophilia A). Relevant as a gene therapy commercialization benchmark and potential strategic acquirer of platform AAV/complement assets.
  • Spark Therapeutics (Roche): Roche-owned gene therapy subsidiary (Luxturna) with AAV ocular and other gene therapy capabilities. Comparable as a commercial-stage AAV gene therapy player; relevant strategic acquirer for ophthalmology-focused gene therapy platforms.
  • Regeneron Pharmaceuticals: Develops Eylea (aflibercept), the standard-of-care anti-VEGF for wet AMD with multi-billion-dollar franchise, and has early-stage pipeline interest in dry AMD/GA. Strategic acquirer profile and relevant comparator for ophthalmology commercial dynamics.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Complement Therapeutics social profiles

Digital presence

Complement Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Complement Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Complement Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Complement Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Complement Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Complement Therapeutics

What does Complement Therapeutics do?

Complement Therapeutics is a clinical-stage biotechnology company developing an investigational AAV2-based gene therapy (CTx001) that delivers mini-CR1 to provide sustained modulation of complement pathways for the treatment of Geographic Atrophy secondary to age-related macular degeneration. The company also operates a proprietary Complement Precision Medicine (CPM) mass spectrometry platform that simultaneously quantifies multiple complement proteins from a single blood sample to support patient stratification and disease monitoring.

Is Complement Therapeutics a public or private company?

Complement Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Complement Therapeutics founded?

Complement Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Complement Therapeutics based?

Complement Therapeutics is headquartered in Munich, Germany, in the Europe region.

How does Complement Therapeutics make money?

One revenue line is on record: gene Therapy Development and Commercialization.

Who are Complement Therapeutics's main competitors?

Direct peers on record are Apellis Pharmaceuticals, Astellas Pharma (Iveric Bio), REGENXBIO, Gyroscope Therapeutics (Novartis), uniQure and Annexon Biosciences. Adverum Biotechnologies is listed as an emerging player. Broad incumbents are BioMarin Pharmaceutical, Spark Therapeutics (Roche) and Regeneron Pharmaceuticals.

Does Complement Therapeutics have an API?

No public API is recorded for Complement Therapeutics.

What industry is Complement Therapeutics in?

Complement Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies), with a secondary code of HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireComplement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMDComplement Therapeutics GmbH (CTx), a clinical-stage biotechnology company based in Munich, announced that the first patient has been dosed in Opti-GAIN, its first-in-human Phase I/II clinical trial of CTx001 in patients with Geographic Atrophy secondary to Age-related Macular Degeneration. The trial is a multi-center study evaluating safety, tolerability, and preliminary efficacy of CTx001 via a single subretinal injection, with dose-escalation in Part 1 followed by dose-expansion in Part 2. The study is being conducted by the company's UK subsidiary alongside the ongoing Pre-GAIN natural history study to support patient selection and novel endpoint evaluation.MorningstarComplement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMDComplement Therapeutics GmbH announced the first patient has been dosed with CTx001 in the Phase I/II Opti-GAIN clinical trial for Geographic Atrophy secondary to Age-related Macular Degeneration. CTx001 is an investigational AAV2-based gene therapy designed to deliver mini-CR1, a complement system modulator, administered via a single subretinal injection. The dose-escalation study is being conducted by the company's UK subsidiary alongside the ongoing Pre-GAIN natural history study, with the goal of evaluating safety, tolerability, and preliminary efficacy of the therapy.pharmaphorumTrends & Insights, January 2026: A pharmaphorum industry reportPharmaphorum's January 2026 Trends & Insights report covers major life sciences developments including Life Biosciences securing FDA IND clearance for ER 100 (partial epigenetic reprogramming therapy entering first-in-human Phase 1 for optic neuropathies), Complement Therapeutics receiving Fast Track designation for CTx001 in geographic atrophy, and Incyte obtaining positive CHMP opinion for Zynyz as first-line SCAC treatment. The report also highlights AI-driven advances in therapeutic design with Basecamp Research's EDEN platform achieving 97% wet lab success rates, manufacturing innovations from ACG and Nemera improving packaging efficiency, and continued oncology activity across multiple mechanisms including ADCs and BTK degraders.PR NewswireComplement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMDComplement Therapeutics GmbH announced that the U.S. Food and Drug Administration has granted Fast Track Designation for CTx001, the company's AAV-based gene therapy candidate for the treatment of Geographic Atrophy secondary to Age-related Macular Degeneration. The therapy previously received FDA IND clearance and will be evaluated in the Opti-GAIN first-in-human Phase I/II clinical trial, with first patient dosing expected in the United States in Q1 2026. Fast Track designation is intended to facilitate development and expedite review by enabling more frequent interactions with the FDA.PR NewswireComplement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMDComplement Therapeutics GmbH (CTx) announced that the FDA has cleared its Investigational New Drug (IND) application for CTx001, an AAV-based gene therapy candidate for Geographic Atrophy secondary to Age-related Macular Degeneration, enabling initiation of the Opti-GAIN Phase I/II clinical trial. The trial will enroll patients across leading retinal centers with first patient dosing expected in the US in Q1 2026, building on insights from the i-GAIN natural history study involving over 230 participants in the UK and US. The company has progressed from a university spinout to a clinical-stage company in four years, with CTx001 designed to deliver long-term modulation of the complement cascade via a truncated Complement Receptor 1.Pulse 2.0Complement Therapeutics: €72 Million Raised To Develop Novel Therapies Targeting Complement-Mediated DiseasesComplement Therapeutics GmbH raised €72 million in a Series A led by Gimv, with participation from BioGeneration Ventures and others. The funding will advance its lead gene therapy CTx001 for geographic atrophy, including a Phase Ib proof-of-concept and a UK natural history study. The company also plans to explore non-ocular indications and expand its complement precision medicine platform.dlvr.itComplement Therapeutics: €72 Million Raised To Develop Novel Therapies Targeting Complement-Mediated DiseasesComplement Therapeutics GmbH secured €72 million in Series A financing led by Gimv to advance its lead gene therapy candidate, CTx001, for geographic atrophy. The company also expanded its board with representatives from the new investors and plans to utilize the funds for clinical proof-of-concept trials and laboratory growth in the UK. This development validates the therapeutic strategy targeting complement-mediated diseases and supports ongoing natural history studies.Biotech FinancesCOMPLÉMENT THERAPEUTICS SIGNE UNE LEVÉE DE 72 M€German biotech Complement Therapeutics announced the closing of a €72 million Series A funding round, led by Belgian investment firm Gimv alongside existing investors Forbion and BioGeneration Ventures. The company intends to use the capital to advance its lead gene therapy candidate, CTx001, for geographic atrophy into clinical trials while expanding its team in Stevenage, UK. This rapid fundraising follows a €5 million seed round raised just one year prior.BioWorldComplement Therapeutics closes $79M A round for gene therapy in geographic atrophyComplement Therapeutics raised €72 million (US$79.4 million) in a series A round to advance a gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The round is the largest series A completed in Europe this year.PR NewswireComplement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated DiseasesComplement Therapeutics GmbH announced the completion of a €72 million Series A financing round to advance its lead gene therapy, CTx001, for geographic atrophy. The investment was led by Gimv and co-led by Forbion, with participation from BioGeneration Ventures, Panakès Partners, Cambridge Innovation Capital, Hadean Ventures, and Seroba Life Sciences. The funds will support clinical proof-of-concept trials for CTx001 and the expansion of laboratory activities in the UK.